Abstracts to Be Presented at EHA
-
Abstracts to Be Presented at EHA
Daratumumab
Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Preliminary Efficacy and Pharmacokinetics Data from a Dose-Escalation Phase I/II Study (oral presentation)Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis
Towards Personalized Medicine Using a Novel Preclinical Model: Identifying Daratumumab as Effective Treatment for Multiple Myeloma
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind